Alnylam to Webcast R&D Day
December 08 2016 - 3:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will webcast its
upcoming R&D Day, including a live video stream, on the
Investors section of the company’s website, www.alnylam.com, on the
morning of December 16, 2016.
Alnylam management and leading physicians will discuss
development candidates from the company’s RNAi therapeutics
pipeline. The event will include presentations from the following
guest speakers:
- Ole Suhr, M.D., Ph.D.Chief Physician
and Gastroenterologist at the Department of Medicine, and Head of
the Amyloid team at the Umeå University Hospital
- Robert Desnick, M.D., Ph.D.Dean for
Genetic & Genomic Medicine, Professor and Chair Emeritus at the
Icahn School of Medicine at Mount Sinai
- John Pasi, MB, ChB, Ph.D., FRCP,
FRCPath, FRCPCHProfessor of Haemostasis and Thrombosis and
Consultant Haematologist at Barts and the London School of Medicine
and Dentistry, Queen Mary, University of London
The meeting will be held on Friday, December 16, 2016 from 8:00
a.m. to 12:00 p.m. ET at the Westin New York at Times Square in New
York City. A replay will be available on the Alnylam website within
48 hours after the event.
About Alnylam PharmaceuticalsAlnylam is a
biopharmaceutical company developing novel therapeutics based on
RNA interference, or RNAi. The company is leading the translation
of RNAi as a new class of innovative medicines. Alnylam’s pipeline
of investigational RNAi therapeutics is focused in 3 Strategic
Therapeutic Areas (STArs): Genetic Medicines, with a broad pipeline
of RNAi therapeutics for the treatment of rare diseases;
Cardio-Metabolic Disease, with a pipeline of RNAi therapeutics
toward genetically validated, liver-expressed disease targets for
unmet needs in cardiovascular and metabolic diseases; and Hepatic
Infectious Disease, with a pipeline of RNAi therapeutics that
address the major global health challenges of hepatic infectious
diseases. In early 2015, Alnylam launched its “Alnylam 2020”
guidance for the advancement and commercialization of RNAi
therapeutics as a whole new class of innovative medicines.
Specifically, by the end of 2020, Alnylam expects to achieve a
company profile with 3 marketed products, 10 RNAi therapeutic
clinical programs – including 4 in late stages of development –
across its 3 STArs. The company’s demonstrated commitment to RNAi
therapeutics has enabled it to form major alliances with leading
companies including Merck, Medtronic, Novartis, Biogen, Roche,
Takeda, Kyowa Hakko Kirin, Cubist, GlaxoSmithKline, Ascletis,
Monsanto, The Medicines Company, and Sanofi Genzyme. In addition,
Alnylam holds an equity position in Regulus Therapeutics Inc., a
company focused on discovery, development, and commercialization of
microRNA therapeutics. Alnylam scientists and collaborators have
published their research on RNAi therapeutics in over 200
peer-reviewed papers, including many in the world’s top scientific
journals such as Nature, Nature Medicine, Nature Biotechnology,
Cell, New England Journal of Medicine, and The Lancet. Founded in
2002, Alnylam maintains headquarters in Cambridge, Massachusetts.
For more information about Alnylam’s pipeline of investigational
RNAi therapeutics, please visit www.alnylam.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161208006101/en/
Alnylam Pharmaceuticals, Inc.Investors and MediaChristine
Regan Lindenboom, 617-682-4340orInvestorsJosh Brodsky,
617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024